Material and methods

Study subjects
The investigated group included 69 kidney transplant recipients (45 males, 24 females) aged 27-65 years in a period between the years 2010 and 2013. Out of this group, 37 recipients developed acute rejection. All rejection episodes were confirmed by biopsy and classified according to histological Banff 07 criteria [25] . Blood samples were obtained from the recipients at 1 day before transplantation and collected at the National Transplantation Organization in Bratislava, Slovakia. The clinical characteristics of the recipients are shown in Table 1 . Immunosuppressive drugs were administered for the first 1-2 days after transplantation as described by Zilinska et al. [26] . Written informed consent for enrolling in the study and for personal data management was obtained from all recipients. The study was approved by the Ethics committee of the University Hospital Bratislava. All the investigations were carried out in accordance with the International Ethical Guidelines and the Declaration of Helsinki.
Genotyping of HLA-G 14 bp polymorphism at exon 8 (3´ UTR)
Genomic DNA was isolated from EDTA-treated peripheral blood samples (2 ml) by a modified salting-out procedure [27] . Genotyping of HLA-G 14-bp polymorphism (rs16375) was performed as described by Hviid et al. [28] . Briefly, DNA was amplified by forward primer 5′GTGATGGGCTGTTTAAAGTGTCACC-3′ and reverse primer 5′GGAAGGAATGCAGTTCAGCATGA-3′ using a PCR cycler (Biometra). A reaction mixture with a total volume of 25 ml contained 50 ng of template DNA, 0.2 mM of each dNTP (Thermofisher), 1 unit of Taq DNA polymerase (Thermofisher), 1.5 mmol MgCl 2 (Thermofisher) and 10 pmol of each specific primer. PCR conditions were 95°C for 3 minutes, followed by 30 cycles (denaturation at 95°C for 1 min, annealing at 64°C for 1 minute and elongation at 72°C for 1 minute) and final elongation at 72°C for 10 minutes. The PCR products were run in 3% agarose gel for 20 minutes and then visualized under UV-light. Fragment size was confirmed using the 100 bp DNA ladder (SBS). PCR fragments of 224 bp (14 bp insertion) and PCR fragments of 210 bp (14 bp deletion) were identified ( Figure 1 ).
T lymphocytes and NK cells [13] . To summarize, HLA-G mediates inhibition of cytotoxic activity of uterine and peripheral blood NK cells and CD8 + T cells, inhibition of the alloproliferative response of CD4 + T cells, inhibition of dendritic cell maturation and activation of regulatory T cells [12] .
The HLA-G gene is 4170 bp long and consists of 8 exons. By an alternative splicing of the primary transcript, 7 HLA-G isoforms can be generated. Four isoforms: HLA-G1, -G2, -G3 and -G4 are membrane bound, whereas three isoforms: HLA-G5, -G6 and -G7 are soluble. Of these, only the HLA-G1 molecule has a structure resembling that of other membrane-bound HLA-I molecules [14] .
The HLA-G gene is characterized by low polymorphism, namely 53 HLA-G alleles, 18 HLA-G proteins and 2 null alleles have been identified to date (IMGT/HLA database, July 2016). The most polymorphic sites that influence HLA-G expression were identified in the 5´ and 3´ noncoding regions. In the 3´UTR (untranslated region) a 14 bp insertion polymorphism (5´-ATTTGTTCATGCCT-3´) has been described, which affects stability of mRNA causing decreased production of most membrane and soluble isoforms [15] . Other polymorphisms in the 3´UTR that can influence mRNA stability and soluble HLA-G level includes SNP at the +3142 position (C/G), at the +3187 (A/G) and +3196 (C/G) [16] .
Several studies have described a protective effect of HLA-G in human allotransplantation such as kidney, liver, heart and lung [6, [17] [18] [19] . In kidney transplant patients, increased soluble HLA-G level was significantly associated with better graft acceptance [8, 18, [20] [21] [22] [23] . As the expression of sHLA-G may be influenced by the 14 bp insertion polymorphism [15] , the possible association between this variant and graft acceptance has been investigated, but the results are controversial. Out of 5 studies, only 2 studies described association between the HLA-G 14-bp insertion (ins) /deletion (del) polymorphism and risk of kidney transplant rejection [24] . Misra et al. [22] evaluated the relationship between the 14 bp ins/del polymorphism of the HLA-G gene and the level of soluble HLA-G in kidney graft acceptance. The level of soluble HLA-G was found to be increased among the non-acute rejection group for 14 bp ins/ins (P < 0.0001), ins/del (P = 0.0171) and del/del (P = 0.0263) genotypes in comparison to the acute rejection group [22] . The present study further investigates the association between HLA-G 14 bp polymorphism, soluble HLA-G level and kidney graft acceptance in the Slovak Caucasian population. 
HLA-G 14 bp polymorphism in kidney transplant recipients
HLA-G 14 bp insertion/deletion polymorphism in kidney transplant recipients were determined by genotyping. 2 groups of recipients were analyzed: those with acute rejection (N = 37) and those with stable allograft function (N = 32). Allele and genotype frequencies of the HLA-G 14 bp deletion/insertion polymorphism (-14/+14) are shown in Table 2 . Genotype frequencies fit the Hardy-Weinberg equilibrium (P = 0.34). No statistically significant differences were found between the HLA-G 14 bp deletion/ insertion allele and genotypes between the rejection group and non-rejection group (P > 0.05). Nevertheless, in the group with non-rejection higher frequencies
Analysis of soluble HLA-G level
Plasma samples were obtained from transplant recipients (N = 69) 1 day before transplantation. Levels of soluble HLA-G antigens (shed HLA-G1 and secreted HLA-G5) were determined by sandwich enzyme-linked immunosorbent assay (ELISA) using sHLA-G ELISA assay kit (Exbio, Prague, Czech Republic) according to the manufacturer's instructions. Optical density was measured at 450 nm. The limit of sensitivity was 3 U/ml. 100 U sHLA-G corresponds to 40-50 ng of protein.
Data analysis
Allele and genotype frequencies were calculated by chisquare test using SNPstats web software available at http.//bioinfo.iconcologia.net/snpstats/start.htm.
The odds ratios (OR) and 95% confidence intervals (95% CI) were also calculated. For comparison of the mean values of sHLA-G unpaired Student's t test with Welch correction was used. This statistical analysis was performed by InStat statistical software (GraphPad Software, Inc., San Diego, USA. P value of < 0.05 was considered as statistically significant.
Results
Characteristics of kidney transplant recipients
The clinical characteristics of the recipients are shown in Table 1 . The study group of 69 kidney transplant recipients (45 males, 24 females) was divided into recipients with acute rejection (N = 37) and recipients with stable graft function (N = 32). The comparison of demographic and clinical data didn't reveal any significant differences between these analyzed groups ( Table 1 ). The mean age of kidney transplant recipients was 46.05 ± 11.72 years. Out of 69 kidney transplant recipients, 65 underwent first transplantation, whereas 4 recipients underwent second transplantation. Four recipients received kidney from living donors, whereas other recipients received kidney from deceased donors. The mean cold ischemic time was 0.71 ± 0.22 (1 = 24 h). Out of 37 recipients with acute rejection, 20 developed antibody-mediated rejection (AMR), 11 developed T cell -mediated rejection (TCMR) and 6 recipients developed both types of rejection. In relation to HLA mismatch between donor and recipient, 7.25% of kidney transplant recipients had Fig. 1 . HLA-G 14 bp ins/del genotyping by PCR. HLA-G 14 bp ins/ del polymorphism in kidney transplant recipients was assessed by PCR [28] . PCR fragment of 224 bp (14 bp insertion, +14) and PCR fragment of 210 bp (14 bp deletion, -14) was identified.
acute rejection (22.723 ± 17.063 vs. 15.625 ± 9.172 U/ml, P = 0.0409, Figure 2 ). Analysis of sHLA-G values in the group with acute rejection revealed no association between the values and type of rejection (AMR: 13.439 ± 6.628 U/ml, TCMR: 17.377 ± 12.143 U/ml, AMR+TCMR: 19.705 ± 9.900 U/ ml, P > 0.05, Figure 3 ).
Analysis of soluble HLA-G level in association with 14 bp ins/del polymorphism in kidney transplant recipients
Pre-transplantation sHLA-G level was also analyzed, in association with HLA-G 14 bp ins/del polymorphism genotype in kidney transplant recipients. First, the level of soluble HLA-G was determined in all kidney transplant recipients regardless of rejection (Figure 4) . Significantly of homozygous -14/-14 bp genotype and decreased frequencies of heterozygous -14/+14 bp genotype were observed in comparison to recipients with acute rejection (43.75% vs. 27.03% and 31.25% vs. 54.05%). After adjustment for age and gender there were no significant changes in the distributions of the HLA-G 14 bp deletion/ insertion polymorphism (Table 2 ).
Analysis of soluble HLA-G level in kidney transplant recipients
Levels of soluble HLA-G were analyzed by ELISA in kidney transplant recipients plasma 1 day before transplantation. Plasma from 69 recipients was evaluated. Significantly higher levels of sHLA-G were found in the group with stable allograft function in comparison to group with Fig. 2 . Pre-transplantation sHLA-G levels in kidney transplant recipients. sHLA-G values were expressed as mean±SD. P values were calculated using unpaired Student's t test with Welch correction. * P value of < 0.05 was considered as statistically significant. AR -acute rejection, STA -stable allograft function, N -number Fig. 3 . Pre-transplantation sHLA-G levels in kidney transplant acute rejection recipients. sHLA-G values were expressed as mean ± SD. P values were calculated using Student's t test with Welch correction. * P value of < 0.05 was considered as statistically significant. AMR -antibody -mediated rejection, TCMR -T cell -mediated rejection, N -number higher levels of sHLA-G were found in the homozygous -14/-14 recipients in comparison to the homozygous +14/+14 recipients (25.115 ± 18.422 vs. 14.455 ± 6.831 U/ml, P = 0.0153) and to the heterozygous -14/+14 individuals (25.115 ± 18.422 vs. 16.190 ± 10.199, P = 0.0408). In the group with stable allograft function, significantly higher values of sHLA-G were found in the homozygous -14/-14 individuals in comparison to the acute rejection recipients (32.939 ± 20.578 vs. 14.162 ± 5.201, P = 0.0052, Figure 5 ). However, there was no association of sHLA-G values and +14/+14 genotype or -14/+14 genotype in the group with stable allograft function as compared to the group with acute rejection (14.519 ± 6.502 vs. 14.381 ± 7.717, P = 0.9172; 14.985 ± 8.343 vs. 16.793 ± 11.164, P = 0.6235).
Discussion
HLA-G is a non-classical HLA-class I molecule that suppress the immune response. The HLA-G molecule inhibits cytotoxic activity of NK cells and cytotoxic T cells, alloproliferative response of CD4 + T cells, dendritic cells maturation and activation of regulatory T cells [12] . In relation to these characteristics, a protective effect of HLA-G in human allotransplantation such as kidney, liver, heart and lung has been described [6, [17] [18] [19] . As gene polymorphism can influence protein expression level, the association between HLA-G 14 bp ins/del polymorphism in the 3´UTR, soluble HLA-G level and kidney graft acceptance in the Slovak population was analyzed. It was found that the HLA-G 14 bp insertion polymorphism in the 3´UTR is responsible for a decrease in the mRNA level of most membrane and soluble isoforms [15] . The possible impact of the HLA-G 14 bp variant on kidney graft be up-regulated by stressors such as hypoxia, cytokines like IFN-g, TNF, IL-10, TGF-b, immunosuppressive agents or progressive doses of progesterone [34, 35] . In relation to HLA-G expression, the time-course of serum HLA-G in patients after kidney transplantation has been examined by only few studies to date [18, 31] . First, the decrease of pre-transplantation sHLA-G in the first 2 weeks after renal transplantation was observed. In the period between 1-12 months after transplantation, an increase of sHLA-G level was found in patients without rejection while no change was observed in recipients with graft rejection. The explanation of such HLA-G expression is mostly unknown and needs to be elucidated more precisely. It was observed that individual immunosuppressive agents can decrease HLA-G expression; however the sHLA-G levels are still higher in patients without rejection [35] . acceptance has been investigated by various authors, but the results are controversial. Findings of HLA-G 14bp genotyping in kidney transplant recipients of various origins are summarized in Table 3 . In the present study, 69 kidney graft recipients of Caucasian origin were genotyped. No statistically significant differences were found between the HLA-G 14 bp deletion/insertion allele and genotypes between kidney transplant rejection group and non-rejection group. This observation is in agreement with data reported by others [29, 30] . In the group with non kidney graft rejection higher frequencies of homozygous -14/-14 bp genotype were observed in comparison to recipients with acute rejection, as confirmed by others [21, 22] . A statistically significant increase of the HLA-G 14 bp ins/ins genotype in the acute rejection group, as reported by [21, 22] , was not confirmed in this study.
Many studies observed that higher serum HLA-G level or HLA-G mRNA expression is associated with kidney graft acceptance [8, 18, [20] [21] [22] [23] 26, 31] . The authors have suggested that soluble HLA-G could be used as additional marker to monitor the graft acceptance outcome. In the present study also, significantly higher pre-transplantation levels of sHLA-G were found in the group without rejection in comparison to group with acute rejection. Rebmann et al. [18] showed that pre-transplantation level of sHLA-G < 11.5 ng/ml (sensitivity 60%; specificity 80.4%) is significantly related to rejection. In the present study the pre-transplantation level of sHLA-G < 15.625 ± 9.172 U/ml was significantly related to kidney graft rejection.
The association between the HLA-G 14 bp ins/del polymorphism, soluble HLA-G level and graft acceptance has been analyzed only by few studies to date [22, 32, 33] . Torres et al. [32] and Misra et al. [22] found increased pre-transplantation levels of sHLA-G for 14 bp del/del genotypes in the non-acute kidney and heart graft rejection group as compared to acute rejection recipients. However, data by Waterhouse et al. [33] suggest a weak involvement of 14-bp polymorphism on HLA-G gene expression and sHLA-G concentration in allogeneic hematopoietic cell transplantation outcome. In the present study, significantly higher pre-transplantation values of soluble HLA-G in the homozygous -14/-14 individuals were found in comparison to the homozygous +14/+14 individuals followed by heterozygous -14/+14 individuals. In the group with stable allograft function significantly higher pre-transplantation levels of sHLA-G were detected in the association with 14 bp deletion polymorphism genotype. However, in the group with acute rejection no such HLA-G genotype association was found. It can be hypothesized that the level of HLA-G in these recipients is influenced by other biological factors. It was shown that HLA-G expression can Fig. 4 . HLA-G 14 bp ins/del polymorphism and pre-transplantation sHLA-G levels in kidney transplant recipients. sHLA-G values were expressed as mean±SD. P values were calculated using unpaired Student's t test with Welch correction. * P value of <0.05 was considered as statistically significant. +14 -HLA-G 14 bp insertion in exon 8, -14 -HLA-G 14 bp deletion in exon 8, N -number sHLA-G values were expressed as mean ± SD. P values were calculated using unpaired Student's t test with Welch correction. * P value of < 0.05 was considered as statistically significant. +14 -HLA-G 14 bp insertion in exon 8, -14 -HLA-G 14 bp deletion in exon 8, ARacute rejection, STA -stable allograft function, N -number To conclude, this is the first study examining the association between the HLA-G 14 bp insertion/deletion polymorphism, soluble HLA-G level and kidney graft acceptance in the Slovak Caucasian population. The results have shown that increased soluble HLA-G level is associated with 14 bp deletion polymorphism leading to kidney graft acceptance. Further detailed HLA-G analysis is planned and it is suggested that the pre-transplantation level of sHLA-G should be monitored as an independent soluble marker to predict kidney graft acceptance. 
